JP7847084B2 - ジストロフィン関連タンパク質複合体（ｄａｐｃ）を回復および維持するための組成物および方法 - Google Patents

ジストロフィン関連タンパク質複合体（ｄａｐｃ）を回復および維持するための組成物および方法

Info

Publication number
JP7847084B2
JP7847084B2 JP2022535865A JP2022535865A JP7847084B2 JP 7847084 B2 JP7847084 B2 JP 7847084B2 JP 2022535865 A JP2022535865 A JP 2022535865A JP 2022535865 A JP2022535865 A JP 2022535865A JP 7847084 B2 JP7847084 B2 JP 7847084B2
Authority
JP
Japan
Prior art keywords
seq
sarcoglycan
essentially
dystrophin
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022535865A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023506030A5 (https=
JP2023506030A (ja
Inventor
エリック ポジュガイ，
ルイーズ ロディーノ－クラパック，
Original Assignee
リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル
サレプタ セラピューティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル, サレプタ セラピューティクス， インコーポレイテッド filed Critical リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル
Publication of JP2023506030A publication Critical patent/JP2023506030A/ja
Publication of JP2023506030A5 publication Critical patent/JP2023506030A5/ja
Priority to JP2025087309A priority Critical patent/JP2025139591A/ja
Application granted granted Critical
Publication of JP7847084B2 publication Critical patent/JP7847084B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4707—Muscular dystrophy
    • C07K14/4708—Duchenne dystrophy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1719—Muscle proteins, e.g. myosin or actin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
JP2022535865A 2019-12-16 2020-12-15 ジストロフィン関連タンパク質複合体（ｄａｐｃ）を回復および維持するための組成物および方法 Active JP7847084B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025087309A JP2025139591A (ja) 2019-12-16 2025-05-26 ジストロフィン関連タンパク質複合体（ｄａｐｃ）を回復および維持するための組成物および方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962948586P 2019-12-16 2019-12-16
US62/948,586 2019-12-16
US202063023144P 2020-05-11 2020-05-11
US63/023,144 2020-05-11
PCT/US2020/065157 WO2021126880A1 (en) 2019-12-16 2020-12-15 Compositions and methods for restoring and maintaining the dystrophin-associated protein complex (dapc)

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025087309A Division JP2025139591A (ja) 2019-12-16 2025-05-26 ジストロフィン関連タンパク質複合体（ｄａｐｃ）を回復および維持するための組成物および方法

Publications (3)

Publication Number Publication Date
JP2023506030A JP2023506030A (ja) 2023-02-14
JP2023506030A5 JP2023506030A5 (https=) 2023-12-22
JP7847084B2 true JP7847084B2 (ja) 2026-04-16

Family

ID=76478281

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022535865A Active JP7847084B2 (ja) 2019-12-16 2020-12-15 ジストロフィン関連タンパク質複合体（ｄａｐｃ）を回復および維持するための組成物および方法
JP2025087309A Pending JP2025139591A (ja) 2019-12-16 2025-05-26 ジストロフィン関連タンパク質複合体（ｄａｐｃ）を回復および維持するための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025087309A Pending JP2025139591A (ja) 2019-12-16 2025-05-26 ジストロフィン関連タンパク質複合体（ｄａｐｃ）を回復および維持するための組成物および方法

Country Status (4)

Country Link
US (1) US20230040544A1 (https=)
EP (1) EP4117783A4 (https=)
JP (2) JP7847084B2 (https=)
WO (1) WO2021126880A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102877920B1 (ko) 2015-11-16 2025-10-30 더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈 티틴-기반 근증 및 다른 티틴성병증의 치료를 위한 물질 및 방법
TWI887479B (zh) * 2020-09-08 2025-06-21 美商薩羅塔治療公司 表現γ-肌聚醣之腺相關病毒載體之全身性遞送及肌肉失養症之治療
EP4198047A1 (en) 2021-12-16 2023-06-21 Genethon Fukutin related protein gene transfer increase using modified itr sequences
EP4198046A1 (en) 2021-12-16 2023-06-21 Genethon Alpha-sarcoglycan gene transfer increase using modified itr sequences
EP4198048A1 (en) 2021-12-16 2023-06-21 Genethon Calpain-3 gene transfer increase using modified itr sequences
CA3259572A1 (en) * 2022-06-30 2024-01-04 Sarepta Therapeutics, Inc. TREATMENT METHODS FOR MUSCULAR DYSTROPHY
CA3257440A1 (en) * 2022-07-06 2024-01-11 Adverum Biotechnologies, Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF ACHROMOTOPSY
AR133921A1 (es) 2023-09-25 2025-11-12 Sarepta Therapeutics Inc Distrofinas humanas adaptadas con mayor afinidad de unión a la actina para el tratamiento de las distrofias musculares
WO2025226842A1 (en) 2024-04-24 2025-10-30 Kate Therapeutics, Inc. Expression control by drg-expressed mirnas
WO2026011009A1 (en) 2024-07-02 2026-01-08 Kate Therapeutics, Inc. Compositions and methods for muscle disorders

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019513399A (ja) 2016-04-15 2019-05-30 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル β−サルコグリカン及びマイクロＲＮＡ−２９のアデノ随伴ウイルスベクター送達ならびに筋ジストロフィーの治療

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999043360A1 (en) * 1998-02-26 1999-09-02 The Trustees Of The University Of Pennsylvania Stable protection from dystrophic sarcolemmal degeneration and restoration of the sarcoglycan complex
US6262035B1 (en) * 1998-10-01 2001-07-17 University Of Iowa Research Foundation Gene replacement therapy for muscular dystrophy
US9434928B2 (en) * 2011-11-23 2016-09-06 Nationwide Children's Hospital, Inc. Recombinant adeno-associated virus delivery of alpha-sarcoglycan polynucleotides
WO2017165859A1 (en) * 2016-03-24 2017-09-28 Research Institute At Nationwide Children's Hospital Modified viral capsid proteins
JP7676111B2 (ja) * 2017-03-17 2025-05-14 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル 筋ジストロフィーを治療するための筋肉特異的マイクロジストロフィンのアデノ随伴ウイルスベクター送達
AR114350A1 (es) * 2018-01-31 2020-08-26 Res Institute At Nationwide Children’S Hospital Terapia genética para la distrofia muscular de cinturas del tipo 2c

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019513399A (ja) 2016-04-15 2019-05-30 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル β−サルコグリカン及びマイクロＲＮＡ−２９のアデノ随伴ウイルスベクター送達ならびに筋ジストロフィーの治療

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Gene Therapy，2016年，23，pp.57-66，doi:10.1038/gt.2015.80
Molecular Therapy，2016年，24(SUPPL. 1)，pp. S246-S247, Abstract Number: 622
Neuromuscular Disorders，2014年，24(9-10)，pp. 885, Abstract Number: G.P.227，DOI 10.1016/j.nmd.2014.06.303
PLoS One，2013年，8(8)，e73224, page 1-17，DOI:10.1371/journal.pone.0073224

Also Published As

Publication number Publication date
US20230040544A1 (en) 2023-02-09
EP4117783A1 (en) 2023-01-18
EP4117783A4 (en) 2024-08-21
JP2025139591A (ja) 2025-09-26
JP2023506030A (ja) 2023-02-14
WO2021126880A1 (en) 2021-06-24

Similar Documents

Publication Publication Date Title
JP7847084B2 (ja) ジストロフィン関連タンパク質複合体（ｄａｐｃ）を回復および維持するための組成物および方法
JP7853354B2 (ja) 筋ジストロフィーを治療するための筋肉特異的マイクロジストロフィンのアデノ随伴ウイルスベクターデリバリー
CN109069672B (zh) 腺相关病毒载体传递微肌营养不良蛋白以治疗肌营养不良症
JP7384797B2 (ja) ムコ多糖症ｉｉｉｂ型のための遺伝子療法
EP2394667A1 (en) Vectors and sequences for the treatment of diseases
JP7389744B2 (ja) ムコ多糖症ｉｉｉａ型のための遺伝子療法
JP7820422B2 (ja) ジスフェリン二重ベクターを用いた遺伝子治療
JP2022512589A (ja) Ｇｍ１ガングリオシドーシスの治療に有用な組成物
JP2025517361A (ja) 好ましい脳、脊髄、および／または心臓発現レベルを有する、選択されたアデノ随伴ウイルス組成物
JP2024529540A (ja) 筋肉及びｃｎｓにおける遺伝子発現のためのハイブリッドプロモーター
US20250369016A1 (en) Muscle tropic raav
EA047041B1 (ru) Генная терапия с использованием двойных векторов дисферлина
TW202613313A (zh) 肌向性ｒａａｖ
TW202607143A (zh) 肌向性ｒａａｖ
TW202432836A (zh) Ｒａａｖ產生方法
WO2025157137A1 (zh) Aav载体、载体组合物、嵌合载体和治疗或预防sma的方法
HK40118571A (zh) 腺相关病毒载体传递微肌营养不良蛋白以治疗肌营养不良症
HK40115222A (zh) 腺相关病毒载体递送肌肉特异性微肌营养不良蛋白以治疗肌营养不良症
TW202603165A (zh) 用於治療杜興氏肌肉失養症之腺相關病毒組成物
HK40126715A (zh) 用於治疗肌营养不良的肌肉特异性微小肌营养不良蛋白的腺相关病毒载体递送

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231214

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231214

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241226

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250318

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250526

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250818

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251217

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260319

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260406

R150 Certificate of patent or registration of utility model

Ref document number: 7847084

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150